STAT+: Servier to buy Edgewise Therapeutics’ muscular dystrophy drug
Andrew Joseph·
·1 min read
·
0 reactions
·
0 comments
·
23 views
The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion upfront.
Original article
STAT · Andrew Joseph
Anonymous · no account needed
Discussion
0 commentsMore from STAT
STAT+: Newer GLP-1s, pushback on research cuts, and a protest
STAT·13
STAT+: Up and down the ladder: The latest comings and goings
STAT·11
STAT+: Will Makary’s FDA voucher program survive?
STAT·12
STAT+: Drug companies, patient groups urge FDA to pause commissioner’s voucher program
STAT·23
Male puberty is understudied — but when it starts may predict long-term health risks
STAT·14
What happens at a longevity festival?
STAT·13